Selected article for: "positive sample and post peak phase"
Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response
  • Document date: 2020_4_14
    • ID: d7stppv5_99
    Snippet: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04. 10.20061325 doi: medRxiv preprint Figure 7 . Projections of remdesivir drug resistance during therapy. Simulations are with moderate potency (EC50=8.0 uM) and the assumption that mutants confer partial drug resistance. Treatment initiation is at timepoints generally consistent with hospitalization (day 10 after first positive sample), fi.....
    Document: is the (which was not peer-reviewed) The copyright holder for this preprint . https://doi.org/10.1101/2020.04. 10.20061325 doi: medRxiv preprint Figure 7 . Projections of remdesivir drug resistance during therapy. Simulations are with moderate potency (EC50=8.0 uM) and the assumption that mutants confer partial drug resistance. Treatment initiation is at timepoints generally consistent with hospitalization (day 10 after first positive sample), first symptoms (day 5 after first positive sample), pre-symptomatic post-peak phase (day 2 after first positive sample) or pre-symptomatic pre-peak phase (day 0). A. Projections of no treatment, treatment with no assumed drug resistance, and treatment with assumed drug resistance. B. Projections of assumed drug resistance with trajectories of sensitive strains, single mutants and double mutants.

    Search related documents:
    Co phrase search for related documents
    • positive sample 10 day and pre peak phase: 1, 2, 3, 4, 5
    • positive sample 10 day and pre symptomatic pre peak phase: 1, 2, 3, 4
    • positive sample 10 day and remdesivir drug resistance: 1, 2
    • positive sample 10 day and treatment initiation: 1, 2, 3, 4, 5
    • positive sample 10 day hospitalization and post peak phase: 1, 2, 3, 4, 5
    • positive sample 10 day hospitalization and pre peak phase: 1, 2, 3, 4, 5
    • positive sample 10 day hospitalization and pre symptomatic pre peak phase: 1, 2, 3, 4
    • positive sample 10 day hospitalization and remdesivir drug resistance: 1, 2
    • positive sample 10 day hospitalization and treatment initiation: 1, 2, 3, 4, 5
    • positive sample and post peak phase: 1, 2, 3, 4, 5, 6
    • post peak phase and pre peak phase: 1, 2, 3, 4, 5, 6, 7, 8
    • post peak phase and pre symptomatic pre peak phase: 1, 2, 3, 4, 5
    • post peak phase and remdesivir drug resistance: 1, 2
    • post peak phase and treatment initiation: 1, 2, 3, 4, 5
    • pre peak phase and remdesivir drug resistance: 1, 2
    • pre peak phase and treatment initiation: 1, 2, 3, 4, 5
    • pre symptomatic pre peak phase and remdesivir drug resistance: 1, 2
    • pre symptomatic pre peak phase and treatment initiation: 1, 2, 3, 4
    • remdesivir drug resistance and treatment initiation: 1, 2